Bayer stock: Berenberg raises price target to EUR 62
Published on 11/18/2026 at 17:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst lifts Bayer outlook
- Berenberg raised its price target for Bayer while retaining a Hold recommendation.
- The analyst sees longer-term scope for Bayer to use proceeds from a possible Monsanto public offering for pharmaceutical development.
- Bayer stock traded below the previous Xetra close on Lang & Schwarz late Wednesday.
Bayer stock traded at 55.90 euros on Lang & Schwarz at 17:15 CET on Wednesday, November 18, 2026, 0.43 percent below the Xetra close of Tuesday, November 17. The fresh corporate signal came from Berenberg, which raised its price target for Bayer to EUR 62.00 from EUR 53.50 while keeping its Hold rating.
MarketScreener, citing dpa-AFX, reported the analyst action on Wednesday. The original study was published on November 17, according to the report.
Long-term pharmaceutical focus
Berenberg analyst Sebastian Bray wrote that Bayer shares had performed strongly during the year. Looking toward the end of the decade, he said Bayer could take Monsanto public and invest the proceeds in pharmaceutical development.
The analyst view adds a new valuation reference to Bayer's recent investor debate, which also includes pharmaceutical growth and the legal burden inherited through Monsanto. The unchanged Hold rating signals that the higher target did not alter Berenberg's overall stance on the stock.
Late session trading
The Lang & Schwarz quote stood below the previous Xetra close late Wednesday. The comparison reflects the latest available market quote and the completed Xetra session from the preceding trading day.
Bayer market facts
- Company: Bayer AG
- ISIN: DE000BAY0017
- Ticker: BAYN.DE
- Lang & Schwarz quote: 55.90 euros at 17:15 CET on Wednesday, November 18, 2026
- Change versus Xetra close: 0.43 percent lower than the 56.14-euro Xetra close on Tuesday, November 17, 2026
German equity market developments are covered in Current market reports.
More news and analyses on Bayer stock.
